Anzeige
Mehr »
Login
Sonntag, 12.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
285 Leser
Artikel bewerten:
(1)

Mile High Labs and Brightfield Group Launch Innovation Platform to Fuel Next Generation of Novel Consumer Products

Finanznachrichten News

BROOMFIELD, Colo., June 23, 2021 /PRNewswire/ -- Mile High Labs is pleased to announce the launch of the Mile High Innovation Lab, a product development platform purpose-built to give brands the confidence to develop, launch and scale new products in the health and wellness industry. Select Partners join the Innovation Lab to leverage Mile High Labs' R&D and manufacturing expertise, Royal DSM's global library of unique vitamin and mineral combinations and Brightfield Group's in-home consumer surveys to bring innovative product concepts to life.

"Think of the Mile High Innovation Lab as a virtualized R&D and consumer panel platform," said Jon Hilley, CEO, Mile High Labs. "It's a way for our Partners to leverage the unique strengths of the world's leading cannabinoid manufacturer in Mile High, the world's leading ingredient company in DSM and the industry's leading consumer insights platform in Brightfield Group. You come with the consumer product ideas, we prototype them, consumers test and you get actionable insights that give you the confidence to commercialize your product."

The Innovation Lab concept is born from the need in the market for a stage-gated, standardized product development process that accelerates the discovery of novel consumer products. It applies lessons learned from established global CPG companies to the cannabinoid market, creating a framework for more precision early in the product development process. Mile High's innovation journey carries each Partner's product ideas all the way from concept to prototype, to consumer testing and feedback, to commercialization with every Partner retaining the intellectual property of their discoveries.

Once concepts are prototyped, samples will be distributed to consumers enrolled in each Partner's virtual consumer panel. After consumers try each sample, Brightfield Group will follow up with In-Home User Testing surveys (IHUTs) which are designed to gauge consumer reactions to the product concept, measure satisfaction levels based on a variety of attributes and identify willingness to purchase. The actionable product insights produced from Brightfield Group's IHUTs help Partners minimize the risk of failure and maximize the commercial opportunity of each new product concept.

"The pace of innovation in CBD is accelerating, giving way to the next generation of products that include additional functional ingredients, minor cannabinoids and need-state focused positionings," said Bethany Gomez, Brightfield Group's Managing Director. "As CBD heads into this next chapter, with retail rebounding and regulatory guidance on the horizon, it will be critical for the industry to apply more discipline and rigor to succeed. The Brightfield/Mile High partnership will put consumers at the heart of the innovation process to create innovative CBD solutions rooted in high-quality data and insights."

"The novel consumer products that will define the next phase of this industry are waiting to be made, and the Mile High Innovation Lab exists to bring these innovations to life," adds Hilley. "I'm excited to see what magic we create together."

The Mile High Innovation Lab is limited to 10 partners. Apply to join by visiting milehighlabs.com/innovation/innovation-lab

About Mile High Labs

Mile High Labs powers the world's novel consumer packaged goods. Our portfolio of legal cannabinoid ingredients and market-ready solutions is trusted by leading global brands, and our formulation and rapid prototyping capabilities are creating the next generation of innovative consumer products. We specialize in the production of hemp cannabinoid-based powders, capsules, tablets and gummies, along with other value-added capabilities. With 400,000 square feet of research and manufacturing facilities in Broomfield, Colorado, as well as third-party fulfillment services to more than 35 countries, we empower customers to confidently develop, launch and scale new products backed by science and integrity. Learn more at milehighlabs.com.

About Brightfield

Brightfield Group is a leading research firm for emerging categories including CBD, Cannabis, and Wellness. Their multi-source methodology integrates artificial intelligence with research expertise into a single platform, powering deeper and more responsive insights for these dynamic industries. Since 2015, Brightfield has helped Marketing, Innovation, and Insights leaders drive customer-centric strategies for their brands. Learn more at brightfieldgroup.com.

Contact:
John Husak
j.husak@milehighlabs.com

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.